Why Donald Bobo Unloaded 5,300 Stock of Edwards Lifesciences (EW)?; Tronox Limited (TROX) Covered By 7 Bullish Analysts Last Week

February 22, 2018 - By Vivian Park

Among 9 analysts covering Tronox (NYSE:TROX), 7 have Buy rating, 1 Sell and 1 Hold. Therefore 78% are positive. Tronox had 19 analyst reports since August 6, 2015 according to SRatingsIntel. On Monday, July 31 the stock rating was maintained by Alembic with “Buy”. The rating was initiated by Wells Fargo with “Buy” on Wednesday, February 7. Alembic maintained Tronox Limited (NYSE:TROX) on Tuesday, August 8 with “Buy” rating. The firm has “Neutral” rating by B. Riley & Co given on Thursday, August 6. The company was maintained on Thursday, November 9 by UBS. The rating was maintained by RBC Capital Markets with “Outperform” on Thursday, August 13. The stock of Tronox Limited (NYSE:TROX) has “Sell” rating given on Wednesday, April 6 by UBS. On Thursday, December 14 the stock rating was initiated by Barclays Capital with “Buy”. Alembic maintained the shares of TROX in report on Monday, June 5 with “Buy” rating. The stock of Tronox Limited (NYSE:TROX) earned “Buy” rating by J.P. Morgan on Tuesday, October 24. See Tronox Limited (NYSE:TROX) latest ratings:

07/02/2018 Broker: Wells Fargo Rating: Buy New Target: $28.0 Initiate
30/01/2018 Broker: Morgan Stanley Rating: Equal-Weight New Target: $21 Initiates Coverage On
25/01/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $23 New Target: $22 Maintain
14/12/2017 Broker: Barclays Capital Rating: Buy New Target: $25.0 Initiate
09/11/2017 Broker: UBS Rating: Sell Old Target: $17 New Target: $18 Maintain
24/10/2017 Broker: JP Morgan Rating: Overweight New Target: $30 Initiates Coverage On
24/10/2017 Broker: J.P. Morgan Rating: Buy New Target: $30.0 Initiate
23/10/2017 Broker: Vertical Research Rating: Buy New Target: $32 Initiates Coverage On
23/10/2017 Broker: Alembic Rating: Buy Maintain
13/10/2017 Broker: UBS Rating: Sell Old Target: $16 New Target: $17 Maintain




Company insider, Donald Bobo, CVP – Strategy/Corp Development of Edwards Lifesciences Corp unloaded a total of 5,300 shares of the corporation, at an average $134.7 per share. In the last 30 days, he also unloaded 9,050 shares worth $1,152,614 USD. This sell was pretty significant, so clearly it won’t go disregarded. Right now, Donald Bobo owns a total of 98,893 shares or 0.05% of the Company’s market capitalization. The trade was disclosed in a SEC document on 21/02/2018.

Investors sentiment increased to 1.14 in 2017 Q3. Its up 0.06, from 1.08 in 2017Q2. It improved, as 19 investors sold Tronox Limited shares while 45 reduced holdings. 34 funds opened positions while 39 raised stakes. 62.74 million shares or 5.69% more from 59.37 million shares in 2017Q2 were reported. Cubist Systematic Strategies Ltd Liability Corp has 0.01% invested in Tronox Limited (NYSE:TROX) for 10,548 shares. Aqr Cap Mgmt invested in 0% or 102,190 shares. Sei Comm holds 144,422 shares or 0.01% of its portfolio. Corsair Mgmt Ltd Partnership reported 0.3% stake. Private Cap Ltd Liability holds 5.32% or 1.66 million shares in its portfolio. The New York-based Virtu Lc has invested 0% in Tronox Limited (NYSE:TROX). Creative Planning owns 161,884 shares or 0.02% of their US portfolio. Pnc Svcs Group Inc accumulated 0% or 60 shares. Schneider Capital Mngmt invested in 0.28% or 72,904 shares. Hanseatic Ser reported 0% of its portfolio in Tronox Limited (NYSE:TROX). Kennedy Cap Mngmt has invested 0.09% in Tronox Limited (NYSE:TROX). Glazer Cap Ltd Llc has invested 0% in Tronox Limited (NYSE:TROX). Hbk L P reported 0.02% in Tronox Limited (NYSE:TROX). Guggenheim Cap Limited Liability Co, Illinois-based fund reported 63,413 shares. Aristotle Cap Boston Ltd Liability Co invested in 0.23% or 120,982 shares.

The stock increased 0.73% or $0.15 during the last trading session, reaching $20.8. About 691,685 shares traded. Tronox Limited (NYSE:TROX) has risen 311.09% since February 22, 2017 and is uptrending. It has outperformed by 294.39% the S&P500.

Tronox Limited produces and markets titanium bearing mineral sands and titanium dioxide pigment in North America, Europe, South Africa, and the Asia-Pacific region. The company has market cap of $2.49 billion. It primarily operates in two divisions, TiO2 and Alkali. It currently has negative earnings. The TiO2 segment engages in the exploration, mining, and beneficiation of mineral sands deposits.

Since September 1, 2017, it had 0 buys, and 2 selling transactions for $357,004 activity. On Friday, September 1 Khilnani Jogita sold $103,900 worth of Tronox Limited (NYSE:TROX) or 5,000 shares. $253,104 worth of stock was sold by van Niekerk Willem Hendrik on Wednesday, September 6.

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp has $195 highest and $86 lowest target. $133.13’s average target is -0.83% below currents $134.25 stock price. Edwards Lifesciences Corp had 106 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Tuesday, September 22 by Zacks. As per Sunday, November 5, the company rating was maintained by RBC Capital Markets. Jefferies maintained Edwards Lifesciences Corporation (NYSE:EW) rating on Monday, April 4. Jefferies has “Buy” rating and $105 target. The company was maintained on Thursday, December 7 by Jefferies. The firm earned “Neutral” rating on Thursday, June 9 by Guggenheim. The rating was maintained by Morgan Stanley with “Overweight” on Thursday, October 26. The firm has “Outperform” rating given on Wednesday, December 7 by Cowen & Co. Deutsche Bank maintained it with “Hold” rating and $115 target in Thursday, October 26 report. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Thursday, July 27 by Canaccord Genuity. JMP Securities reinitiated the stock with “Mkt Perform” rating in Wednesday, January 6 report.

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on April, 24. They expect $1.10 EPS, up 17.02% or $0.16 from last year’s $0.94 per share. EW’s profit will be $231.03 million for 30.51 P/E if the $1.10 EPS becomes a reality. After $0.94 actual EPS reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts 17.02% EPS growth.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $28.20 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 49.72 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts